Dasatinib promotes ATRA-induced differentiation of AML cells

Leukemia

Volumn 24, Issue 3, 2010, Pages 663-665

  Kropf, P L ^a   Wang, L ^a   Zang, Y ^a   Redner, R L ^b   Johnson, D E ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ERLOTINIB; GEFITINIB; HEMATOPOIETIC CELL KINASE; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CELL DIFFERENTIATION; CELL VIABILITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LETTER; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR DIFFERENTIATION;

EID: 77949425397     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.267     Document Type: Letter

References (14)

1. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxy-ethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
2. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926-939.
3. Vandyke K, Dewar AL, Farrugia AN, Fitter S, To LB, Hughes TP, et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009; 23: 994-997.
4. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009; 23: 590-594.
5. Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P, et al. The new tyrosine-kinase inhibitor and anti-cancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114: 1884-1892.
6. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.
7. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 4415-4416.
8. Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Mol Cancer Ther 2007; 6: 3081-3090.
9. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005; 106: 2841-2848.
10. Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, et al. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia 2008; 22: 1624-1627.
11. Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111: 2170-2180.
12. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007; 110: 1079-1080.
13. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008; 26: 3645-3646.
14. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood 2008; 111: 2269-2279.